明星药物Dupixent销售额再创新高！赛诺菲(SNY.US)Q4盈利超预期

Core Viewpoint - Sanofi's strong sales performance of Dupixent has driven better-than-expected earnings for Q4 2025, with continued revenue and profit growth anticipated in 2026 [1] Financial Performance - Q4 2025 net sales reached €11.303 billion, a year-on-year increase of 7.0% (13.3% at constant exchange rates) [2] - Business operating income for Q4 was €2.341 billion, up 12.7% year-on-year [2] - Business net income for Q4 was €1.856 billion, reflecting a 13.0% increase year-on-year [2] - Business earnings per share (EPS) for Q4 was €1.53, a 16.8% increase compared to the previous year [2] - Free cash flow for Q4 was €2.637 billion, up 12.7% year-on-year [2] Product Performance - Dupixent sales grew by 32.2% year-on-year to a record €4.246 billion in Q4, solidifying its position as a key growth driver for Sanofi [2] - The pharmaceutical segment's sales increased by 49.4% to €1.121 billion, primarily driven by Ayvakit and ALTUVIIIO [2] Future Outlook - Sanofi expects sales growth in 2026 to be in the high single-digit percentage range (at constant exchange rates), with business EPS growth slightly exceeding sales growth [3] - The company plans to execute a €1 billion share buyback program in 2026 [3] Challenges and Strategic Focus - Sanofi's vaccine business faced a 2.5% decline in Q4 sales to €2.039 billion, with expectations of a slight decrease in vaccine sales for 2026 [3] - CEO Paul Hudson expressed optimism about sustained profit growth for at least five years, but emphasized the need for a robust pipeline to reduce reliance on Dupixent [4] - Recent disappointing trial results for new drugs have raised concerns about Sanofi's ability to generate sufficient revenue from upcoming products [4] - The company has written down €2.24 billion, primarily related to the failed multiple sclerosis drug tolebrutinib [4] Strategic Initiatives - Following the divestiture of its consumer health business, Sanofi is focused on demonstrating the success of its "pure innovation" strategy [5] - The company has engaged in significant partnerships, including a $1.04 billion collaboration with ADEL for an early-stage Alzheimer's antibody and a potential $1.7 billion deal with Dren Bio to enhance its autoimmune platform [5]